Literature DB >> 11074544

High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura.

H M Tsai1.   

Abstract

Acute thrombotic thrombocytopenic purpura is a disease with diffuse platelet thrombi in the microcirculation. Despite plasma exchange therapy, approximately 20 percent of the patients succumb to the disease. A significant number of the survivors suffer one or more relapses. This study investigated the activity of von Willebrand factor-cleaving metalloproteinase and the titers of IgG inhibitors to the proteinase in serial plasma samples from a patient who died during a relapse of the disease despite continued plasma exchanges. A deficiency in the von Willebrand factor-cleaving metalloproteinase activity, due to inhibitory IgG, was detected at presentation. After initiation of plasma exchange, a transient increase in proteinase activity coincided with clinical remission. When thrombocytopenia relapsed, the activity of the proteinase also declined to undetectable levels. Toward the end of her course, proteinase levels raised by plasma exchange were not sustained because the proteinase activity was quickly neutralized by rising titers of inhibitors. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase cause refractoriness to standard plasma therapy. These findings suggest that intensive plasma exchanges and measures that suppress antibody titers may prevent death and promote remission in refractory cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11074544     DOI: 10.1002/1096-8652(200011)65:3<251::aid-ajh13>3.0.co;2-2

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

Review 1.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

Review 2.  Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2008-07       Impact factor: 3.443

Review 3.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 4.  Thrombotic thrombocytopenic purpura: survival by "giving a dam".

Authors:  Joel L Moake
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

5.  ADAMTS13 is expressed in hepatic stellate cells.

Authors:  Wenhua Zhou; Mari Inada; Tai-Ping Lee; Daniel Benten; Sergey Lyubsky; Eric E Bouhassira; Sanjeev Gupta; Han-Mou Tsai
Journal:  Lab Invest       Date:  2005-06       Impact factor: 5.662

Review 6.  Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Evolution of ADAMTS13 antibodies in a fatal case of thrombotic thrombocytopenic purpura.

Authors:  Lingli Dong; Visalam Chandrasekaran; Wenhua Zhou; Han-Mou Tsai
Journal:  Am J Hematol       Date:  2008-10       Impact factor: 10.047

Review 8.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

9.  High-dose immunoglobulin infusion for thrombotic thrombocytopenic purpura refractory to plasma exchange and steroid therapy.

Authors:  Seh Jong Park; Seok Jin Kim; Hee Yun Seo; Moon Ju Jang; Doyeun Oh; Byung Soo Kim; Jun Suk Kim
Journal:  Korean J Intern Med       Date:  2008-09       Impact factor: 2.884

Review 10.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.